Nagata et al., 2008 - Google Patents
15 Anti-Infective Vaccine StrategiesNagata et al., 2008
- Document ID
- 9928063681903545570
- Author
- Nagata T
- Koide Y
- Publication year
- Publication venue
- Handbook of Listeria Monocytogenes
External Links
Snippet
Listeria monocytogenes is a Gram-positive, opportunistic intracellular bacterium that can cause serious diseases (eg, meningitis and death) in immunocompromised hosts, pregnant women, and neonates. 1–3 During the course of its infection, L. monocytogenes employs a …
- 229960005486 vaccines 0 title description 198
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Silva et al. | Live bacterial vaccine vectors: an overview | |
| EP1921149A1 (en) | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof | |
| Kotton et al. | Enteric pathogens as vaccine vectors for foreign antigen delivery | |
| JP4662925B2 (en) | Tuberculosis vaccine with improved efficiency | |
| Roland et al. | Recent advances in the development of live, attenuated bacterial vectors | |
| US20060140975A1 (en) | Regulated bacterial lysis for gene vaccine vector delivery and antigen release | |
| JP2005006659A (en) | Methods for introducing and expressing genes in animal cells | |
| WO2011060431A2 (en) | Multivalent live vector vaccine against clostridium difficile-associated disease | |
| US7829104B2 (en) | Electroporation of Mycobacterium and overexpression of antigens in mycobacteria | |
| EP1504095A2 (en) | Site specific listeria integration vectors and methods for using the same | |
| JP5713523B2 (en) | Recombinant BCG strains with enhanced endosome escape ability | |
| Medina et al. | Pathogenicity island 2 mutants of Salmonella typhimurium are efficient carriers for heterologous antigens and enable modulation of immune responses | |
| HK1213008A1 (en) | Facultatively attenuated bacterial species and methods of preparation and use thereof | |
| US7939089B2 (en) | Attenuated mycobacteria as vectors for gene delivery to mammalian cells | |
| HUP0201117A2 (en) | Attenuated microorganisms for the treatment of infection | |
| DIETRICH et al. | Bacterial systems for the delivery of eukaryotic antigen expression vectors | |
| Kochi et al. | Advances in the development of bacterial vector technology | |
| JP2010538649A (en) | Method for enhancing transgene expression from bacterial-based delivery systems by co-expression of eukaryotic type I interferon response suppressors - Patents.com | |
| US20220001008A1 (en) | Live self-destructing bacterial adjuvants to enhance induction of immunity | |
| EP1326960B1 (en) | Microbes having an attenuating mutation comprising a transcription terminator | |
| Xu et al. | Attenuated Salmonella and Shigella as carriers for DNA vaccines | |
| AU2001292051B2 (en) | Stabilisation of plasmid inheritance in bacteria by preventing multimerisation | |
| CN101048178B (en) | Combinations of recombinant mycobacteria and bioactive agents as vaccines | |
| Dietrich et al. | Haemolysin A and listeriolysin–two vaccine delivery tools for the induction of cell-mediated immunity | |
| Nagata et al. | 15 Anti-Infective Vaccine Strategies |